Camber Capital Management Lp - Net Worth and Insider Trading
Camber Capital Management Lp Net Worth
The estimated net worth of Camber Capital Management Lp is at least $245 Million dollars as of 2024-05-09. Camber Capital Management Lp is the 10% Owner of Sequenom Inc and owns about 51,429,565 shares of Sequenom Inc (SQNM) stock worth over $123 Million. Camber Capital Management Lp is the 10% Owner of Cardiovascular Systems Inc and owns about 6,057,000 shares of Cardiovascular Systems Inc (CSII) stock worth over $121 Million. Camber Capital Management Lp is also the 10% Owner of Protalix BioTherapeutics Inc and owns about 1,077,500 shares of Protalix BioTherapeutics Inc (PLX) stock worth over $1 Million. Besides these, Camber Capital Management Lp also holds AMAG Pharmaceuticals Inc (AMAG) . Details can be seen in Camber Capital Management Lp's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Camber Capital Management Lp has not made any transactions after 2020-10-01 and currently still holds the listed stock(s).
Transaction Summary of Camber Capital Management Lp
Camber Capital Management Lp Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Camber Capital Management Lp owns 6 companies in total, including AMAG Pharmaceuticals Inc (AMAG) , Endologix Inc (ELGXQ) , and Protalix BioTherapeutics Inc (PLX) among others .
Click here to see the complete history of Camber Capital Management Lp’s form 4 insider trades.
Insider Ownership Summary of Camber Capital Management Lp
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| AMAG | AMAG Pharmaceuticals Inc | 2020-10-01 | 10 percent owner |
| ELGXQ | Endologix Inc | 2018-10-29 | 10 percent owner |
| PLX | Protalix BioTherapeutics Inc | 2016-12-02 | 10 percent owner |
 | | 2016-09-20 | 10 percent owner |
| | 2016-01-04 | 10 percent owner |
| | 2023-03-17 | 10 percent owner |
Camber Capital Management Lp Latest Holdings Summary
Camber Capital Management Lp currently owns a total of 4 stocks. Among these stocks, Camber Capital Management Lp owns 51,429,565 shares of Sequenom Inc (SQNM) as of January 4, 2016, with a value of $123 Million and a weighting of 50.09%. Camber Capital Management Lp owns 6,057,000 shares of Cardiovascular Systems Inc (CSII) as of September 20, 2016, with a value of $121 Million and a weighting of 49.36%. Camber Capital Management Lp also owns 1,077,500 shares of Protalix BioTherapeutics Inc (PLX) as of December 2, 2016, with a value of $1 Million and a weighting of 0.55%. The other 1 stocks AMAG Pharmaceuticals Inc (AMAG) have a combined weighting of 0% among all his current holdings.
Latest Holdings of Camber Capital Management Lp
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| SQNM | Sequenom Inc | 2016-01-04 | 51,429,565 | 2.39 | 122,916,660 |
| CSII | Cardiovascular Systems Inc | 2016-09-20 | 6,057,000 | 20.00 | 121,140,000 |
| PLX | Protalix BioTherapeutics Inc | 2016-12-02 | 1,077,500 | 1.25 | 1,346,875 |
| AMAG | AMAG Pharmaceuticals Inc | 2020-10-01 | 0 | 13.75 | 0 |
Holding Weightings of Camber Capital Management Lp
Camber Capital Management Lp Form 4 Trading Tracker
According to the SEC Form 4 filings, Camber Capital Management Lp has made a total of 0 transactions in Sequenom Inc (SQNM) over the past 5 years. The most-recent trade in Sequenom Inc is the acquisition of 665,435 shares on January 4, 2016, which cost Camber Capital Management Lp around $1 Million.
According to the SEC Form 4 filings, Camber Capital Management Lp has made a total of 0 transactions in Cardiovascular Systems Inc (CSII) over the past 5 years. The most-recent trade in Cardiovascular Systems Inc is the sale of 1,100,000 shares on September 20, 2016, which brought Camber Capital Management Lp around $26 Million.
According to the SEC Form 4 filings, Camber Capital Management Lp has made a total of 0 transactions in Protalix BioTherapeutics Inc (PLX) over the past 5 years. The most-recent trade in Protalix BioTherapeutics Inc is the sale of 250,000 shares on December 2, 2016, which brought Camber Capital Management Lp around $800,000.
More details on Camber Capital Management Lp's insider transactions can be found in the Insider Trading History of Camber Capital Management Lp table.Insider Trading History of Camber Capital Management Lp
- 1
Camber Capital Management Lp Trading Performance
GuruFocus tracks the stock performance after each of Camber Capital Management Lp's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Camber Capital Management Lp is 6.29%. GuruFocus also compares Camber Capital Management Lp's trading performance to market benchmark return within the same time period. The performance of stocks bought by Camber Capital Management Lp within 3 months outperforms 4 times out of 8 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Camber Capital Management Lp's insider trading performs compared to the benchmark.
Performance of Camber Capital Management Lp
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 0.16 | | | | | |
| Relative Return to S&P 500(%) | 1.88 | | | | | |
Camber Capital Management Lp Ownership Network
Camber Capital Management Lp Owned Company Details
What does AMAG Pharmaceuticals Inc do?
Who are the key executives at AMAG Pharmaceuticals Inc?
Camber Capital Management Lp is the 10 percent owner of AMAG Pharmaceuticals Inc. Other key executives at AMAG Pharmaceuticals Inc include Chief Operating Officer Anthony Casciano , Interim CFO Brian Piekos , and director & 10 percent owner David Edward Johnson .
AMAG Pharmaceuticals Inc (AMAG) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of AMAG Pharmaceuticals Inc (AMAG) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of AMAG Pharmaceuticals Inc (AMAG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
AMAG Pharmaceuticals Inc (AMAG)'s detailed insider trading history can be found in Insider Trading Tracker table.
AMAG Pharmaceuticals Inc Insider Transactions
Camber Capital Management Lp Mailing Address
Above is the net worth, insider trading, and ownership report for Camber Capital Management Lp. You might contact Camber Capital Management Lp via mailing address: 101 Huntington Avenue, Suite 2101, Boston Ma 02199.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
